Acurx Pharmaceuticals, LLC*(ACXP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ACXP Acurx Pharmaceuticals, LLC*

交易中 08-17 15:37:50 EDT

1.58

+0.19

+13.26%

最高1.82	最低1.39	成交量105.51万
今开1.40	昨收1.40	日振幅30.75%
总市值832.64万	流通市值658.56万	总股本526.99万
成交额174.13万	换手率25.31%	流通股本416.81万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ACXP","market":"US","secType":"STK","nameCN":"Acurx Pharmaceuticals, LLC*","latestPrice":1.58,"timestamp":1786995452993,"preClose":1.395,"halted":0,"volume":1055134,"delay":0,"changeRate":0.13261648745519716,"floatShares":4168100,"shares":5269900,"eps":-2.787323,"marketStatus":"交易中","change":0.185,"latestTime":"08-17 15:37:50 EDT","open":1.4,"high":1.8172,"low":1.3883,"amount":1741292.8103566,"amplitude":0.307455,"askPrice":1.59,"askSize":50,"bidPrice":1.57,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-2.787323,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1786996800000},"marketStatusCode":2,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":1.395,"preHourTrading":{"tag":"盘前","latestPrice":1.4068,"preClose":1.395,"latestTime":"08:38 EDT","volume":26081,"amount":35626.8103103,"timestamp":1786970335933,"change":0.0118,"changeRate":0.008459,"amplitude":0.055054},"postHourTrading":{"tag":"盘后","latestPrice":1.38,"preClose":1.395,"latestTime":"19:55 EDT","volume":9190,"amount":12749.1348,"timestamp":1786751742851,"change":-0.015,"changeRate":-0.010753,"amplitude":0.021505},"volumeRatio":4.539192,"impliedVol":1.1448,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/ACXP","defaultTab":"news","newsList":[{"id":"1170841586","title":"Acurx Pharmaceuticals获FDA条件性接受及USPTO商标许可，确立Ibezapolstat品牌名","url":"https://stock-news.laohu8.com/highlight/detail?id=1170841586","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170841586?lang=zh_cn&edition=full","pubTime":"2026-08-17 20:02","pubTimestamp":1786968135,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals宣布，其用于Ibezapolstat的公司品牌名已获得美国食品药品监督管理局（FDA）的条件性接受，同时美国专利商标局（USPTO）也对该商标予以许可。这一进展标志着公司在推进这一候选药物商业化进程中迈出重要一步。FDA的接受与USPTO的商标许可，共同为Ibezapolstat的未来市场推广奠定了品牌基础。Acurx Pharmaceuticals表示，此举有助于强化其产品识别度，并为后续监管审批及上市准备铺平道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACXP","BK4539","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133956816","title":"Acurx与莱顿大学医学中心达成科学合作，推进DNA聚合酶IIIc抑制剂抗生素研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1133956816","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133956816?lang=zh_cn&edition=full","pubTime":"2026-08-10 20:04","pubTimestamp":1786363469,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals, LLC* 宣布与莱顿大学医学中心建立科学合作伙伴关系。此次合作旨在加速该公司旗下DNA聚合酶IIIc抑制剂类抗生素的研发进程。双方将共同推动这一前沿抗菌药物的开发，这一举措有望为耐药性感染治疗领域带来新的突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4539","ACXP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144857769","title":"Acurx Pharmaceuticals 获FDA松口：若单次III期试验疗效数据扎实，可提前讨论NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=1144857769","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144857769?lang=zh_cn&edition=full","pubTime":"2026-08-03 20:02","pubTimestamp":1785758534,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals 迎来利好信号——美国食品药品监督管理局（FDA）表态，若其单一III期临床试验的疗效结果足够强劲，公司将获准就新药申请（NDA）展开前期讨论。这一进展意味着，即便Acurx仅完成一项关键试验，只要数据达到“稳健”标准，监管机构也愿意提前介入沟通。对这家专注于感染性疾病药物研发的公司而言，这无疑为后续审批路径增添了更多确定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4563","ACXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150441542","title":"FDA为Acurx Pharmaceuticals的Ibezapolstat临床开发项目提供进一步监管指导，包括单次三期试验注册计划及支持治疗与降低艰难梭菌感染复发的试验设计","url":"https://stock-news.laohu8.com/highlight/detail?id=1150441542","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150441542?lang=zh_cn&edition=full","pubTime":"2026-08-03 20:01","pubTimestamp":1785758484,"startTime":"0","endTime":"0","summary":"FDA向Acurx Pharmaceuticals提供了针对Ibezapolstat临床开发项目的进一步监管指导。这一指导涵盖了潜在的单次三期试验注册计划，以及一项旨在支持治疗并降低艰难梭菌感染复发的试验设计。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4563","ACXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133739531","title":"FDA认可Acurx Pharmaceuticals新药申请：治疗与降低复发可能性并存","url":"https://stock-news.laohu8.com/highlight/detail?id=1133739531","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133739531?lang=zh_cn&edition=full","pubTime":"2026-08-03 20:01","pubTimestamp":1785758470,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已同意，若临床试验顺利推进，Acurx Pharmaceuticals可同时提交针对两种适应症的新药申请（NDA）。这其中包括直接治疗，以及有效降低疾病复发风险的双重目标。一旦试验结果达标，NDA的递交将不再是单一维度的突破，而是一种并行推进的策略。Acurx Pharmaceuticals因此迎来重大转机，其研发管线的前景也愈加清晰。此番进展，标志着该公司在抗菌药物领域迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","ACXP","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160155349","title":"Acurx Pharmaceuticals 将于2026年8月14日召开电话会议讨论2026年第二季度财务业绩并提供业务更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1160155349","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160155349?lang=zh_cn&edition=full","pubTime":"2026-07-08 20:01","pubTimestamp":1783512089,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals 计划于2026年8月14日举行一场电话会议。届时，公司管理层将详细介绍其2026年第二季度的财务业绩，并向投资者和公众提供最新的业务进展信息。此次会议旨在保持与市场的透明沟通，分享公司在战略发展、产品管线及运营方面的关键动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4563","ACXP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141312126","title":"Acurx制药公司公布其DNA聚合酶IIIC抑制剂在莱顿大学医学中心公私合作项目中的研究结果，并于莱顿早期药物发现与开发科学会议上展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1141312126","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141312126?lang=zh_cn&edition=full","pubTime":"2026-06-16 20:03","pubTimestamp":1781611404,"startTime":"0","endTime":"0","summary":"Acurx制药公司宣布，其针对DNA聚合酶IIIC抑制剂的研究成果，在莱顿大学医学中心主导的公私合作项目中取得进展。这些关键数据已在莱顿早期药物发现与开发科学会议上进行展示。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACXP","BK4539","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116754985","title":"Acurx Pharmaceuticals将于2026年5月12日召开电话会议 讨论2026年第一季度财务业绩并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1116754985","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116754985?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:05","pubTimestamp":1776686737,"startTime":"0","endTime":"0","summary":"生物制药公司Acurx Pharmaceuticals宣布，计划于2026年5月12日举行投资者电话会议，届时将详细介绍公司2026年第一季度的财务业绩。此次会议不仅将披露关键财务数据，管理层还将同步更新公司最新的业务发展动态与战略规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4563","ACXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147786136","title":"Acurx制药公司宣布以纳斯达克规则市价发行上限710万美元的直接注册发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1147786136","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147786136?lang=zh_cn&edition=full","pubTime":"2026-04-16 20:07","pubTimestamp":1776341234,"startTime":"0","endTime":"0","summary":"Acurx制药公司今日宣布，将根据纳斯达克市场规则进行一项最高金额达710万美元的直接注册发行，发行价格将按市价执行。此次融资计划旨在为公司研发管线提供资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","ACXP","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113858949","title":"Acurx制药公司：自2026年4月1日起，CEO兼执行董事长年薪降至49.5万美元，CFO年薪降至36万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1113858949","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113858949?lang=zh_cn&edition=full","pubTime":"2026-03-09 21:13","pubTimestamp":1773062013,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件显示，Acurx Pharmaceuticals, LLC* 已决定调整其高管的薪酬水平。自2026年4月1日起，公司首席执行官兼执行董事长的年薪将调整为49.5万美元。与此同时，首席财务官的年薪也将同步下调至36万美元。此次薪酬调整反映了公司在特定发展阶段对成本结构的优化考量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4563","BK4139","ACXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166486536","title":"Acurx Pharmaceuticals 艰难梭菌感染项目即将启动三期国际临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1166486536","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166486536?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:06","pubTimestamp":1773058008,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Inc. 宣布，其针对艰难梭菌感染（CDI）的研发项目已准备就绪，即将进入第三期国际临床试验阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","ACXP","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124246629","title":"Acurx Pharmaceuticals Inc - Rcdi试验本月启动，首例患者预计2026年第四季度入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1124246629","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124246629?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:06","pubTimestamp":1773057979,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Inc 宣布，针对Rcdi的临床试验将于本月正式启动，预计首例患者将在2026年第四季度完成入组。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4539","BK4139","ACXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164107747","title":"Acurx Pharmaceuticals启动新型Ibezapolstat临床试验项目，有望革新复发性艰难梭菌感染防治格局","url":"https://stock-news.laohu8.com/highlight/detail?id=1164107747","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164107747?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:05","pubTimestamp":1773057904,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals宣布针对复发性艰难梭菌感染患者推出全新Ibezapolstat临床试验计划。该创新疗法展现出颠覆现有艰难梭菌感染防治范式的巨大潜力，或将重新定义临床治疗标准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","ACXP","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614017880","title":"Acurx Pharmaceuticals, Inc.盘中异动 股价大涨5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614017880","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2614017880?lang=zh_cn&edition=full","pubTime":"2026-02-27 03:46","pubTimestamp":1772135198,"startTime":"0","endTime":"0","summary":"北京时间2026年02月27日03时46分，Acurx Pharmaceuticals, Inc.股票出现波动，股价急速拉升5.16%。Acurx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.94%。Acurx Pharmaceuticals, Inc.公司简介：Acurx Pharmaceuticals Inc 是一家临床阶段的生物制药公司，开发一类新型抗生素，用于治疗由世界卫生组织、疾病控制和预防中心以及食品和药物管理局列为优先病原体的细菌引起的感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022703463997a73227&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022703463997a73227&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ACXP","BK4139","BK4539","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613621553","title":"Acurx Pharmaceuticals, Inc.盘中异动 大幅下挫5.48%报1.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613621553","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2613621553?lang=zh_cn&edition=full","pubTime":"2026-02-21 01:59","pubTimestamp":1771610367,"startTime":"0","endTime":"0","summary":"北京时间2026年02月21日01时59分，Acurx Pharmaceuticals, Inc.股票出现异动，股价大幅跳水5.48%。Acurx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.06%。Acurx Pharmaceuticals, Inc.公司简介：Acurx Pharmaceuticals Inc 是一家临床阶段的生物制药公司，开发一类新型抗生素，用于治疗由世界卫生组织、疾病控制和预防中心以及食品和药物管理局列为优先病原体的细菌引起的感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022101592795418a4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022101592795418a4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","ACXP","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517691029","title":"Acurx Pharmaceuticals, Inc.盘中异动 大幅拉升7.30%报0.669美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517691029","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517691029?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:32","pubTimestamp":1741185149,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时32分，Acurx Pharmaceuticals, Inc.股票出现波动，股价大幅拉升7.30%。截至发稿，该股报0.669美元/股，成交量4100股，换手率0.02%，振幅0.00%。Acurx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。Acurx Pharmaceuticals, Inc.公司简介：Acurx Pharmaceuticals Inc是一家处于临床阶段的生物制药公司，正在开发一种新型抗生素，用于治疗由世界卫生组织、疾病控制和预防中心以及食品药品监督管理局列为优先病原体的细菌所引起的感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223230989d461e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223230989d461e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ACXP","BK4539","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516670975","title":"Acurx Pharmaceuticals, Inc.盘中异动 股价大跌5.91%报0.631美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516670975","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516670975?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:02","pubTimestamp":1741100550,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时02分，Acurx Pharmaceuticals, Inc.股票出现异动，股价急速跳水5.91%。截至发稿，该股报0.631美元/股，成交量4.7923万股，换手率0.25%，振幅4.48%。Acurx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.14%。Acurx Pharmaceuticals, Inc.公司简介：Acurx Pharmaceuticals Inc是一家处于临床阶段的生物制药公司，正在开发一种新型抗生素，用于治疗由世界卫生组织、疾病控制和预防中心以及食品药品监督管理局列为优先病原体的细菌所引起的感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304230230989bb561&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304230230989bb561&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ACXP","BK4563","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514018442","title":"Acurx Pharmaceuticals, Inc.盘中异动 急速下跌7.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514018442","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514018442?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:57","pubTimestamp":1740495451,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时57分，Acurx Pharmaceuticals, Inc.股票出现波动，股价大幅下挫7.97%。Acurx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.07%。Acurx Pharmaceuticals, Inc.公司简介：Acurx Pharmaceuticals Inc是一家处于临床阶段的生物制药公司，正在开发一种新型抗生素，用于治疗由世界卫生组织、疾病控制和预防中心以及食品药品监督管理局列为优先病原体的细菌所引起的感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225225731962ff8a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225225731962ff8a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4539","ACXP","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513722487","title":"Acurx Pharmaceuticals, Inc.盘中异动 早盘大幅下挫5.44%报0.740美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513722487","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513722487?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:38","pubTimestamp":1740407915,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时38分，Acurx Pharmaceuticals, Inc.股票出现波动，股价快速跳水5.44%。Acurx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。Acurx Pharmaceuticals, Inc.公司简介：Acurx Pharmaceuticals Inc是一家处于临床阶段的生物制药公司，正在开发一种新型抗生素，用于治疗由世界卫生组织、疾病控制和预防中心以及食品药品监督管理局列为优先病原体的细菌所引起的感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223835abdb0f96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223835abdb0f96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4563","BK4539","ACXP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513296882","title":"Acurx Pharmaceuticals, Inc.盘中异动 股价大涨8.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513296882","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513296882?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:30","pubTimestamp":1740148240,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时30分，Acurx Pharmaceuticals, Inc.股票出现异动，股价大幅拉升8.41%。Acurx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Acurx Pharmaceuticals, Inc.公司简介：Acurx Pharmaceuticals Inc是一家处于临床阶段的生物制药公司，正在开发一种新型抗生素，用于治疗由世界卫生组织、疾病控制和预防中心以及食品药品监督管理局列为优先病原体的细菌所引起的感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223040962b7b02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223040962b7b02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4539","BK4563","ACXP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.acurxpharma.com","stockEarnings":[{"period":"1week","weight":-0.0942},{"period":"1month","weight":-0.2029},{"period":"3month","weight":-0.2734},{"period":"6month","weight":-0.2919},{"period":"1year","weight":-0.713},{"period":"ytd","weight":-0.4398}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Acurx Pharmaceuticals, Inc.于2017年7月在特拉华州注册成立，于2018年2月开始运营。该公司是一家后期生物制药公司，专注于开发用于难治疗细菌感染的新型小分子抗生素，用于治疗被世界卫生组织列为优先病原体的细菌引起的感染（“WHO”），美国疾病控制与预防中心（“CDC”）和美国食品和药物管理局（“FDA”）。优先病原体是那些需要新抗生素来解决由WHO、CDC和FDA确定的全球抗微生物药物耐药性（“AMR”）危机的病原体。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.08634},{"month":2,"riseRate":0,"avgChangeRate":-0.144545},{"month":3,"riseRate":0.4,"avgChangeRate":0.164663},{"month":4,"riseRate":0.4,"avgChangeRate":-0.083182},{"month":5,"riseRate":0.4,"avgChangeRate":-0.056147},{"month":6,"riseRate":0.4,"avgChangeRate":0.051493},{"month":7,"riseRate":0,"avgChangeRate":-0.145307},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.07806},{"month":9,"riseRate":0,"avgChangeRate":-0.115354},{"month":10,"riseRate":0.6,"avgChangeRate":0.545147},{"month":11,"riseRate":0.2,"avgChangeRate":-0.181708},{"month":12,"riseRate":0.4,"avgChangeRate":-0.094208}],"exchange":"NASDAQ","name":"Acurx Pharmaceuticals, LLC*","nameEN":"Acurx Pharmaceuticals, LLC*"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Acurx Pharmaceuticals, LLC*(ACXP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Acurx Pharmaceuticals, LLC*(ACXP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Acurx Pharmaceuticals, LLC*,ACXP,Acurx Pharmaceuticals, LLC*股票,Acurx Pharmaceuticals, LLC*股票老虎,Acurx Pharmaceuticals, LLC*股票老虎国际,Acurx Pharmaceuticals, LLC*行情,Acurx Pharmaceuticals, LLC*股票行情,Acurx Pharmaceuticals, LLC*股价,Acurx Pharmaceuticals, LLC*股市,Acurx Pharmaceuticals, LLC*股票价格,Acurx Pharmaceuticals, LLC*股票交易,Acurx Pharmaceuticals, LLC*股票购买,Acurx Pharmaceuticals, LLC*股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Acurx Pharmaceuticals, LLC*(ACXP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Acurx Pharmaceuticals, LLC*(ACXP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}